BeiGene (NASDAQ:BGNE) Sees Large Volume Increase – Should You Buy?

Shares of BeiGene, Ltd. (NASDAQ:BGNE) saw unusually-high trading volume on Monday . Approximately 1,411,044 shares were traded during mid-day trading, an increase of 421% from the previous session’s volume of 270,992 shares.The stock last traded at $214.19 and had previously closed at $215.00.

Wall Street Analyst Weigh In

BGNE has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price objective on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 22nd. StockNews.com downgraded BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. TD Cowen lifted their target price on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. JMP Securities initiated coverage on BeiGene in a research note on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 target price on the stock. Finally, Citigroup lifted their target price on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.07.

BeiGene Trading Down 2.6 %

The stock has a fifty day moving average of $212.42 and a 200-day moving average of $184.77. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The company has a market cap of $20.39 billion, a PE ratio of -26.09 and a beta of 0.63.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company’s revenue was up 28.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.01 earnings per share. Sell-side analysts anticipate that BeiGene, Ltd. will post -5.38 EPS for the current fiscal year.

Insider Buying and Selling at BeiGene

In other news, insider Xiaodong Wang sold 40,468 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total value of $7,692,966.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO John Oyler sold 6,175 shares of the company’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,538 shares of company stock worth $12,594,017. 7.43% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BeiGene

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Baillie Gifford & Co. grew its position in BeiGene by 0.6% in the third quarter. Baillie Gifford & Co. now owns 3,705,756 shares of the company’s stock worth $831,979,000 after acquiring an additional 23,807 shares during the period. FMR LLC raised its stake in BeiGene by 0.8% in the third quarter. FMR LLC now owns 1,660,011 shares of the company’s stock valued at $372,689,000 after buying an additional 12,855 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of BeiGene by 74.9% during the third quarter. Point72 Asset Management L.P. now owns 667,166 shares of the company’s stock worth $149,785,000 after purchasing an additional 285,784 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of BeiGene by 160.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock worth $50,706,000 after purchasing an additional 138,978 shares in the last quarter. Finally, TD Asset Management Inc increased its position in shares of BeiGene by 1.4% during the second quarter. TD Asset Management Inc now owns 114,378 shares of the company’s stock worth $16,318,000 after purchasing an additional 1,599 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.